FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173033398> ?p ?o ?g. }

• W3173033398 abstract "Background: Gemcitabine-Cisplatin (GP) chemotherapy is the standard first-line treatment for recurrent or metastatic (RM) Nasopharyngeal Carcinoma (NPC). Toripalimab, a humanized monoclonal antibody specific for human programmed death-1 (PD-1), provided durable responses in patients with RM-NPC in the second line+ setting.Methods: In this international phase III trial, 289 patients with RM-NPC with no prior chemotherapy in the RM setting were randomized (1:1) to receive either toripalimab or placebo in combination with GP every 3 weeks for up to 6 cycles, followed by monotherapy with toripalimab or placebo until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) as assessed by a blinded independent review committee per RECIST v1.1.RESULTSAt interim analysis, a significant improvement in PFS was detected in the toripalimab arm than the placebo arm, median PFS 11.7 vs. 8.0 months, HR=0.52 (95% CI: 0.36-0.74), p=0.0003. As of February 18, 2021, a 40% reduction in risk of death was observed in the toripalimab arm than the placebo arm, HR=0.603 (95% CI: 0.364 to 0.997). The incidence of Grade ≥3 adverse events (AEs) (89.0% vs 89.5%), AEs leading to discontinuation of toripalimab/placebo (7.5% vs 4.9%), and fatal AEs (2.7% vs 2.8%) were similar between two arms; however, immune-related (irAEs) (39.7% vs. 18.9%) and Grade ≥3 irAEs (7.5% vs. 0.7%) were more frequent in the toripalimab arm.Conclusions: The addition of toripalimab to GP chemotherapy as a first-line treatment for patients with RM-NPC provided superior PFS and OS than GP alone with a manageable safety profile.Trial Registration: NCT number NCT03581786.Funding: Shanghai Junshi Biosciences Co., LTD, Shanghai, China.Declaration of Interest: Hui Feng and Sheng Yao are employed by Shanghai Junshi Bioscience andTopAlliance Biosciences. Patricia Keegan is employed by TopAlliance Biosciences.Rui-hua Xu has served in a consulting or an advisory role for Bristol-Myers Squibb,Merck Serono, Roche, Astellas, AstraZeneca.The rest of authors have no disclosures of potential conflicts of interests.Ethical Approval: This trial was conducted in full conformance with the ICH E6 guideline for GoodClinical Practice (GCP) and the principles of the Declaration of Helsinki." @default.
• W3173033398 created "2021-06-22" @default.
• W3173033398 creator A5001528113 @default.
• W3173033398 creator A5004890734 @default.
• W3173033398 creator A5005126432 @default.
• W3173033398 creator A5006423482 @default.
• W3173033398 creator A5012492614 @default.
• W3173033398 creator A5015370659 @default.
• W3173033398 creator A5020746135 @default.
• W3173033398 creator A5022814916 @default.
• W3173033398 creator A5024495179 @default.
• W3173033398 creator A5025689639 @default.
• W3173033398 creator A5025738678 @default.
• W3173033398 creator A5026136156 @default.
• W3173033398 creator A5028840611 @default.
• W3173033398 creator A5028950420 @default.
• W3173033398 creator A5029215411 @default.
• W3173033398 creator A5032868375 @default.
• W3173033398 creator A5039944755 @default.
• W3173033398 creator A5043993720 @default.
• W3173033398 creator A5044138401 @default.
• W3173033398 creator A5044825014 @default.
• W3173033398 creator A5057769470 @default.
• W3173033398 creator A5060591448 @default.
• W3173033398 creator A5061589915 @default.
• W3173033398 creator A5062637798 @default.
• W3173033398 creator A5064526474 @default.
• W3173033398 creator A5066468331 @default.
• W3173033398 creator A5069224733 @default.
• W3173033398 creator A5071145010 @default.
• W3173033398 creator A5072947899 @default.
• W3173033398 creator A5077268765 @default.
• W3173033398 creator A5078326314 @default.
• W3173033398 creator A5079423095 @default.
• W3173033398 creator A5086758549 @default.
• W3173033398 creator A5089211608 @default.
• W3173033398 creator A5089544801 @default.
• W3173033398 date "2021-01-01" @default.
• W3173033398 modified "2023-10-12" @default.
• W3173033398 title "JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma" @default.
• W3173033398 doi "https://doi.org/10.2139/ssrn.3826212" @default.
• W3173033398 hasPublicationYear "2021" @default.
• W3173033398 type Work @default.
• W3173033398 sameAs 3173033398 @default.
• W3173033398 citedByCount "0" @default.
• W3173033398 crossrefType "journal-article" @default.
• W3173033398 hasAuthorship W3173033398A5001528113 @default.
• W3173033398 hasAuthorship W3173033398A5004890734 @default.
• W3173033398 hasAuthorship W3173033398A5005126432 @default.
• W3173033398 hasAuthorship W3173033398A5006423482 @default.
• W3173033398 hasAuthorship W3173033398A5012492614 @default.
• W3173033398 hasAuthorship W3173033398A5015370659 @default.
• W3173033398 hasAuthorship W3173033398A5020746135 @default.
• W3173033398 hasAuthorship W3173033398A5022814916 @default.
• W3173033398 hasAuthorship W3173033398A5024495179 @default.
• W3173033398 hasAuthorship W3173033398A5025689639 @default.
• W3173033398 hasAuthorship W3173033398A5025738678 @default.
• W3173033398 hasAuthorship W3173033398A5026136156 @default.
• W3173033398 hasAuthorship W3173033398A5028840611 @default.
• W3173033398 hasAuthorship W3173033398A5028950420 @default.
• W3173033398 hasAuthorship W3173033398A5029215411 @default.
• W3173033398 hasAuthorship W3173033398A5032868375 @default.
• W3173033398 hasAuthorship W3173033398A5039944755 @default.
• W3173033398 hasAuthorship W3173033398A5043993720 @default.
• W3173033398 hasAuthorship W3173033398A5044138401 @default.
• W3173033398 hasAuthorship W3173033398A5044825014 @default.
• W3173033398 hasAuthorship W3173033398A5057769470 @default.
• W3173033398 hasAuthorship W3173033398A5060591448 @default.
• W3173033398 hasAuthorship W3173033398A5061589915 @default.
• W3173033398 hasAuthorship W3173033398A5062637798 @default.
• W3173033398 hasAuthorship W3173033398A5064526474 @default.
• W3173033398 hasAuthorship W3173033398A5066468331 @default.
• W3173033398 hasAuthorship W3173033398A5069224733 @default.
• W3173033398 hasAuthorship W3173033398A5071145010 @default.
• W3173033398 hasAuthorship W3173033398A5072947899 @default.
• W3173033398 hasAuthorship W3173033398A5077268765 @default.
• W3173033398 hasAuthorship W3173033398A5078326314 @default.
• W3173033398 hasAuthorship W3173033398A5079423095 @default.
• W3173033398 hasAuthorship W3173033398A5086758549 @default.
• W3173033398 hasAuthorship W3173033398A5089211608 @default.
• W3173033398 hasAuthorship W3173033398A5089544801 @default.
• W3173033398 hasConcept C126322002 @default.
• W3173033398 hasConcept C141071460 @default.
• W3173033398 hasConcept C142724271 @default.
• W3173033398 hasConcept C143998085 @default.
• W3173033398 hasConcept C168563851 @default.
• W3173033398 hasConcept C197934379 @default.
• W3173033398 hasConcept C203092338 @default.
• W3173033398 hasConcept C204787440 @default.
• W3173033398 hasConcept C27081682 @default.
• W3173033398 hasConcept C2776694085 @default.
• W3173033398 hasConcept C2778715236 @default.
• W3173033398 hasConcept C2780258809 @default.
• W3173033398 hasConcept C2780739268 @default.
• W3173033398 hasConcept C31760486 @default.
• W3173033398 hasConcept C61943457 @default.
• W3173033398 hasConcept C71924100 @default.
• W3173033398 hasConcept C90924648 @default.
• W3173033398 hasConceptScore W3173033398C126322002 @default.
• W3173033398 hasConceptScore W3173033398C141071460 @default.

• next